O. Fernández

Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (The Novo Study)

G. Izquierdo, I. Boscá, T. Arbizu, 2010, Journal of Neurology.

Multiple sclerosis prevalence in Malaga, Southern Spain estimated by the capture–recapture method

E. de Ramón, O Fernández, M. Romero, 2012, Multiple sclerosis.

The prevalence of multiple sclerosis in the Sanitary District of Vélez‐Málaga, southern Spain

O. Fernández, M. Bravo, G. Luque, 1994, Neurology.

Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial

D. Arnold, A. Traboulsee, Kunio Nakamura, 2021, Therapeutic advances in neurological disorders.

Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management

G. Comi, C. Pozzilli, L. Kappos, 2018, European journal of neurology.

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Margaret Burnett, Gavin Giovannoni, 2018, The Lancet.

Survey of diagnostic and treatment practices for multiple sclerosis in Europe

G. Comi, C. Pozzilli, L. Kappos, 2017, European journal of neurology.

Treatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study)

L. Hernandez, O. Fernández, T. Ayuso, 2017, PloS one.

Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis

O. Fernández, Ó. Fernández, 2012, Journal of central nervous system disease.